165 related articles for article (PubMed ID: 15741205)
1. Pegylated interferon for the treatment of hepatitis C virus in haemodialysis patients.
Teta D; Lüscher BL; Gonvers JJ; Francioli P; Phan O; Burnier M
Nephrol Dial Transplant; 2005 May; 20(5):991-3. PubMed ID: 15741205
[No Abstract] [Full Text] [Related]
2. Peripheral nervous system involvement in a haemodialysis patient treated with pegylated interferon.
Ruiz-Fuentes MC; Rubert-Gómez De Quero A; De Gracia-Guindo C; Galindo-Sacristán P; Osuna-Ortega A
Nefrologia; 2012; 32(6):863-5. PubMed ID: 23169385
[No Abstract] [Full Text] [Related]
3. Treatment of hepatitis C in hemodialysis patients with pegylated interferon alpha-2a as monotherapy.
Sikole A; Dzekova P; Selja N; Gaseva M; Nikolov IG; Zabzun M; Muharemi S; Asani A; Amitov V; Mena S; Grunevska V; Ivanovski L; Polenakovic M
Ren Fail; 2007; 29(8):961-6. PubMed ID: 18067041
[TBL] [Abstract][Full Text] [Related]
4. Acute polymyositis during treatment of acute hepatitis C with pegylated interferon alpha-2b.
Venezia G; Licata A; Di Marco V; Craxì A; Almasio PL
Dig Liver Dis; 2005 Nov; 37(11):882-5. PubMed ID: 16169301
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous occurrence of pleural effusion and interstitial pneumonitis after treatment with pegylated interferon for hepatitis C virus infection.
Ji F; Li Z; Xue H; Liu L; Deng H
South Med J; 2011 Feb; 104(2):140-2. PubMed ID: 21206334
[TBL] [Abstract][Full Text] [Related]
6. Adverse drug effects and pegylation.
Wooten JM
South Med J; 2011 Feb; 104(2):83-4. PubMed ID: 21206333
[No Abstract] [Full Text] [Related]
7. Peginterferon alfa-2b vs. peginterferon alfa-2a in the treatment of hepatitis C, is there any difference?
Sierra F
J Hepatol; 2007 Feb; 46(2):349; author reply 349-50. PubMed ID: 17161495
[No Abstract] [Full Text] [Related]
8. [Sarcoidosis associated with the treatment of hepatitis C: case report and Spanish literature review].
Trullàs JC; Hernández-Marcet P; Bisbe J
Med Clin (Barc); 2011 May; 136(14):649-50. PubMed ID: 21051060
[No Abstract] [Full Text] [Related]
9. Hepatitis C treatment, HAART and side effects.
TreatmentUpdate; 2001; 13(7):7-8. PubMed ID: 11794865
[No Abstract] [Full Text] [Related]
10. [Secondary hemophagocytic syndrome due to Peg-interferon administration].
Ruiz Ramos J
Farm Hosp; 2014 Jan; 38(1):73-4. PubMed ID: 24483865
[No Abstract] [Full Text] [Related]
11. Reply to issues raised in the Jansen/Reesink editorial.
Silva M
J Hepatol; 2007 Feb; 46(2):350-1. PubMed ID: 17161883
[No Abstract] [Full Text] [Related]
12. Quality of life with pegylated interferon therapy for hepatitis C.
Brown RS
Hepatology; 2002 Sep; 36(3):767-8; author reply 768. PubMed ID: 12198677
[No Abstract] [Full Text] [Related]
13. Interferon for hepatitis C patients with psychiatric disorders.
Asnis GM; De La Garza R; Rego SA; Henderson MA; Reinus JF
Am J Psychiatry; 2004 Dec; 161(12):2332; author reply 2332-4. PubMed ID: 15569920
[No Abstract] [Full Text] [Related]
14. Pilot study of pegylated interferon-alpha 2a in dialysis patients with chronic hepatitis C virus infection.
Chan TM; Ho SK; Tang CS; Tse KC; Lam MF; Lai KN; Yung S
Nephrology (Carlton); 2007 Feb; 12(1):11-7. PubMed ID: 17295655
[TBL] [Abstract][Full Text] [Related]
15. Interferon for hepatitis C patients with psychiatric disorders.
Rifai MA; Bozorg B; Rosenstein DL
Am J Psychiatry; 2004 Dec; 161(12):2331-2; author reply 2332-4. PubMed ID: 15569919
[No Abstract] [Full Text] [Related]
16. [Treatment with pegylated interferon and ribavirin in patients co-infected by human immunodeficiency virus and hepatitis C virus].
Marcos Sánchez F; Albo Castaño MI; Casallo Blanco S
Rev Clin Esp; 2007 Mar; 207(3):150-1; author reply 151-2. PubMed ID: 17397643
[No Abstract] [Full Text] [Related]
17. Acute rejection of non-functional allograft in kidney transplant recipients with hepatitis C treated with peginterferon-alpha 2a.
Sperl J; Petrasek J; Spicak J; Viklicky O
J Hepatol; 2008 Sep; 49(3):461-2; author reply 462-3. PubMed ID: 18644649
[No Abstract] [Full Text] [Related]
18. Anti-Golgi complex antibodies during pegylated-interferon therapy for hepatitis C.
Paraná R; Schinoni MI; de Freitas LA; Codes L; Cruz M; Andrade Z; Trepo C
Liver Int; 2006 Nov; 26(9):1148-54. PubMed ID: 17032416
[TBL] [Abstract][Full Text] [Related]
19. Pegylated interferon-α2a versus pegylated interferon-α2b in hepatitis C: reappraisal of effectiveness on the basis of trial sequential analysis.
Messori A; Fadda V; Maratea D; Trippoli S; Marinai C
Eur J Gastroenterol Hepatol; 2014 Feb; 26(2):246-8. PubMed ID: 24366456
[No Abstract] [Full Text] [Related]
20. [Long-acting interferon: studies on pegylated interferon].
Ma H; Wang H
Zhonghua Gan Zang Bing Za Zhi; 2002 Feb; 10(1):78-9. PubMed ID: 11856520
[No Abstract] [Full Text] [Related]
[Next] [New Search]
